Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 13/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4532216 | 0.90 | CYP2D6 (0.45) | CYP2D6CHRM2CHRM3CYP2C19CYP3A4 | |
| SCHEMBL4519880 | 0.88 | CYP2D6 (0.42) | CYP2D6CHRM2CHRM3CYP2C19CYP3A4 | |
| SCHEMBL4526744 | 0.87 | CYP2D6 (0.43) | CYP2D6CHRM2CHRM3CYP2C19CYP3A4 | |
| SCHEMBL4528733 | 0.84 | CYP2D6 (0.39) | CYP2D6CHRM2CHRM3CYP2C19CYP3A4 | |
| SCHEMBL4527746 | 0.84 | CYP2D6 (0.39) | CYP2D6CHRM2CHRM3CYP2C19CYP3A4 | |
| SCHEMBL4533000 | 0.81 | CYP2D6 (0.45) | CYP2D6CHRM2CHRM3CYP2C19CYP3A4 | |
| SCHEMBL4534827 | 0.81 | CYP2D6 (0.44) | CYP2D6CHRM2CHRM3CYP2C19CYP3A4 | |
| SCHEMBL4534459 | 0.75 | SIGMAR1 (0.44) | CYP2D6CHRM2CHRM3CYP2C19CYP3A4 | |
| SCHEMBL4237209 | 0.75 | CYP2D6 (0.41) | CYP2D6CHRM2CHRM3CYP2C19CYP3A4 | |
| SCHEMBL4530558 | 0.72 | CYP2D6 (0.40) | CYP2D6CYP2C19CYP3A4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1864984-A1 | TRICYCLIC SPIRO COMPOUND COMPRISING ACYL GROUP BOUND TO NITROGEN ATOM IN THE RING | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | KCNH1, SCN1A, SCN10A | CYP2D6 465/4885CHRM2 4608/4885CHRM3 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.